JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. has showcased innovative advancements in gene therapy at the 7th International Forum of Lysosomal Disorders, highlighting their proprietary J-Brain Cargo technology. This new technology has proven to improve central nervous system drug delivery while reducing liver toxicity in non-climal trials. Such breakthroughs by JCR could pave the way for developing safer and more effective treatments for genetic diseases.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
